848500-02-7

Basic information

• Product Name: (3'-Cyano-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H22N4O2, MW: 302.37
• Synonyms: (3'-Cyano-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H22N4O2, MW: 302.37;[1-(3-Cyano-2-pyridinyl)-4-piperidinyl]carbamic acid 1,1-dimethylethyl;tert-Butyl [1-(3-cyanopyridin-2-yl)piperidin-4-yl]carbamate
• CAS NO: 848500-02-7
• Molecular Formula: C16H22N4O2
• Molecular Weight: 302.37148
• Mol File: 848500-02-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 485.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.18
• PKA: 12.18±0.20(Predicted)
• CAS DataBase Reference: (3'-Cyano-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H22N4O2, MW: 302.37(CAS DataBase Reference)
• NIST Chemistry Reference: (3'-Cyano-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H22N4O2, MW: 302.37(848500-02-7)
• EPA Substance Registry System: (3'-Cyano-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H22N4O2, MW: 302.37(848500-02-7)

Safety Data

• Hazardous Substances Data: 848500-02-7(Hazardous Substances Data)

Usage

General Description

The chemical compound (3'-Cyano-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H22N4O2, MW: 302.37 is a tert-butyl ester of carbaMic acid containing a bipyridine ring. It has a molecular formula of C16H22N4O2 and a molecular weight of 302.37. (3'-Cyano-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H22N4O2, MW: 302.37 is commonly used in organic synthesis and pharmaceutical research due to its unique structure and potential biological activities. Its high purity of 98% or higher makes it a valuable reagent for various chemical reactions and studies.

Upstream product

• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 

Downstream Products

• 1404098-40-3 2-(4-((4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)amino)piperidin-1-yl)nicotinonitrile 
• 1404098-41-4 N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)methanesulfonamide 
• 1404098-42-5 methyl 3-(N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)sulfamoyl)thiophene-2-carboxylate 
• 1404098-43-6 5-chloro-N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)thiophene-2-carboxamide 
• 1404098-44-7 N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-3-morpholino-N-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)propane-1-sulfonamide 
• 1404098-45-8 5-bromo-N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)thiophene-2-carboxamide 
• 1404098-46-9 (3R,5R,7R)-N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)adamantane-1-carboxamide 
• 1404098-47-0 N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzyl)pentanamide 
• 1404097-90-0 N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-4-((2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzamide 
• 1404097-65-9 2-(4-((4-formylbenzyl)amino)piperidin-1-yl)nicotinonitrile 
• 1404097-66-0 N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-formylbenzyl)methanesulfonamide 
• 1404097-67-1 methyl 3-(N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-formylbenzyl)sulfamoyl)thiophene-2-carboxylate 
• 1404097-68-2 5-chloro-N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-formylbenzyl)thiophene-2-carboxamide 
• 1404097-70-6 N-(1-(3-cyanopyridin-2-yl)piperidin-4-yl)-N-(4-formylbenzyl)-3-morpholinopropane-1-sulfonamide 

Relevant articles and documents

Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H, 5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues. In this study, 54 novel (thio)barbituric acid derivatives have been synthesized and evaluated for pharmacological activity. 7h exhibited potent glucose-lowering effects on insulin-resistant HepG2 cells and regulated adiponectin and leptin expression in 3T3-L1 adipocytes. Oral administration of 7h at 25 mg kg-1 day -1 for 4 weeks improved the progression of high fat diet-induced NAFLD by reducing the weight of body, liver, and fat, as well as modulating serum levels of fasting glucose, insulin, triglycerides, LDL-c, ALT, adiponectin and hepatic contents of triglycerides, total cholesterol. H&E stainings revealed that 7h blocked fat deposition in liver and the increase of adipocyte number and size in adipose tissues from NAFLD. Furthermore, treatment with 7h alleviated the obese clinical symptoms, recovered serum biomarkers to appropriate ranges, and improved glucose tolerance by OGTT and IGTT in DIO mice.